A multi-component vaccine for Malaria providing long-lasting immune responses against Plasmodia (1)
This application relates to immunogenic conjugates which elicit an immune response to Plasmodium proteins. This application claims conjugates that include at least one Plasmodium sexual stage surface protein covalently linked to at least one Plasmodium circumsporozoite protein (CSP) or an immunogenic portion of a CSP. Also claimed in the application are conjugates that include at least one sexual stage surface protein covalently linked to at least one immunogenic repeat derived from a Plasmodium CSP. The inventors' data shows that these conjugates also induced long-lasting antibody responses to each of their components, i.e. the vaccine candidates showed both transmission blocking activity and antibodies to the CSP (or portion thereof).
Pending Patent Reference Number(s): IN Patent Application no 1382KOLNP/2011.; CN Patent Application no 200980148315.8; US Patent Application no 13/121,574; E-339-2008/2-IN-04; E-339-2008/2-US-05; E-339-2008/2-EP-03; E-339-2008/2-CN-02; EP Patent Application no 09898532.5